Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed ...

FOR countless people across Ireland, the simple act of laughing, coughing, or rushing for the bus comes with a hidden worry.

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

The Minnesota medtech company’s Altaviva implant just secured FDA approval. It treats urinary urge incontinence, a ...

Deion Sanders said he thinks has more blood clots due to experiencing leg pain after recently being treated for bladder ...

Bladder cancer is one of the most common cancers worldwide. Men are around four times more likely to develop it than women, ...